By Sabela Ojea

Boston Scientific said its clinical trial to treat coronary in-stent restenosis with its investigational device met its primary endpoint, reducing the risk of heart failure.

The biotechnology company said the positive outcomes from its Agent Drug-Coated Balloon support the device as an alternative treatment option for coronary in-stent restenosis.

"We look forward to using these encouraging data to support FDA approval and bringing this important therapy to more physicians and patients in need," said Janarthanan Sathananthan, chief medical officer at interventional cardiology therapies.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

October 25, 2023 15:17 ET (19:17 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Boston Scientific (NYSE:BSX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Boston Scientific.
Boston Scientific (NYSE:BSX)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Boston Scientific.